Two previous meta-analyses across multiple studies and cancer types showed that DCLK1 overexpression correlates with advanced clinical stage, lymph node metastasis, poorly differentiated cancers, poor overall survival, and reduced anti-tumor immune responses within the tumor microenvironment [24,25]. This evidence concerns the gene DCLK1 and neoplasm.